GSK ‘in discussions’ over $1 billion tech deal with Qualcomm
pharmafile | January 21, 2016 | News story | Medical Communications | GSK, beyond the pill, digital pharma, joint venture, qualcomm
GlaxoSmithKline and telecoms giant Qualcomm are reportedly discussing a joint venture agreement worth as much as $1 billion, as the pharma company seeks to expand its presence in the medical technology market.
People familiar with the matter say the talks are preliminary, and that terms of the deal had not been decided. Neither company has yet commented on the reports.
In recent years, pharmaceutical companies have increasingly moved to take their services ‘beyond the pill’, and tie-ins between the industry and technology companies have become more common.
This month, it was revealed Novartis had signed a collaboration agreement with Qualcomm to develop smart inhaler technology for patients with chronic obstructive pulmonary disease (COPD). Qualcomm is also working with Roche on technology to help collate and analyse clinical trial data. Other companies have worked with technology providers, including Google and Apple on health apps, as pharma scrambles not to get left behind the curve in the technological revolution.
A tie-in with Qualcomm would not be GSK’s first move into the technical world. In December, the British drugmaker partnered with US health technology firm Propeller Health to develop an advanced sensor to be used in respiratory clinical trials.
Joel Levy
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …
